FDA to Hold Public Meeting for Patient Perspectives on Psoriasis Treatments

The FDA is holding a public meeting to gain patient perspectives on treatments for psoriasis.

The meeting — scheduled for March 17, 2016 — is part of the agency’s Patient-Focused Drug Development initiative. Under that initiative, the agency plans to obtain patient perspectives on at least 20 disease areas during the course of PDUFA V. For each area, the agency will conduct a public meeting to discuss the disease and its impact on patients' daily lives, the types of treatment benefits that matter most to patients, and patients' perspectives on the adequacy of the available therapies.

The meeting will focus on patients' perspectives for plaque psoriasis, nail psoriasis and guttate psoriasis.

The public can submit comments to www.regulations.gov.